pharmacophorebas
virtual
screen
effect
inexpens
fast
approach
discov
use
start
point
drug
discoveri
studi
develop
pharmacophor
model
main
proteinas
sever
acut
respiratori
syndrom
coronaviru
sarscov
use
pharmacophor
model
search
nci
databas
includ
compound
identifi
exist
drug
contain
pharmacophor
queri
among
six
compound
alreadi
exhibit
antisarscov
activ
experiment
mean
pharmacophor
model
lead
discoveri
potent
antisarscov
inhibitor
promis
lead
compound
sarscov
main
proteinas
inhibitor
develop
infect
newli
emerg
sever
acut
respiratori
syndrom
coronaviru
sarscov
character
acut
flulik
symptom
progress
acut
lung
injuri
acut
respiratori
distress
syndrom
mortal
date
univers
recommend
therapi
diseas
mani
scientist
make
effort
develop
effect
drug
sar
combin
therapi
corticosteroid
lopinavir
ribavirin
ritonavir
improv
clinic
respons
reduc
mortal
rate
appar
cinatl
et
al
found
ribavirin
azauridin
pyrazofurin
glycyrrhizin
activ
sarscov
barnard
et
al
report
calpain
inhibitor
bdn
hydroxycytidin
exhibit
inhibitori
effect
sarscov
structurebas
drug
design
focus
two
import
approach
one
receptorbas
dock
techniqu
anoth
pharmacophorebas
virtual
screen
techniqu
pharmacophor
arrang
atom
function
group
essenti
compound
bind
specif
receptor
power
pharmacophor
model
discov
new
lead
use
databas
pharmacophor
search
guid
chemist
synthes
new
compound
pharmacophorebas
method
success
appli
mani
drug
develop
program
main
proteinas
sarscov
play
import
role
viru
replic
primari
target
drug
aim
studi
develop
pharmacophor
model
sarscov
main
proteinas
expect
provid
use
knowledg
antisar
drug
design
two
method
deriv
reason
pharmacophor
model
one
crystal
structur
proteinligand
complex
anoth
base
molecular
model
enzym
potenti
inhibitor
use
experiment
structur
sarscov
main
proteinas
complex
peptid
inhibitor
cmk
pdb
id
predict
structur
sarscov
main
proteinas
six
drugscompound
establish
pharmacophor
model
structur
cmk
peptid
six
compound
shown
fig
pocket
modul
ligbuild
program
employ
obtain
pharmacophor
model
sarscov
main
proteinas
approach
success
appli
identif
novel
inhibitor
alanin
racemas
propos
pharmacophor
model
bindingsitederiv
pharmacophor
model
includ
follow
pharmacophor
featur
ligand
bind
enzym
activ
site
posit
charg
nitrogen
atom
ammonium
cation
repres
hydrogen
bond
donor
hbd
neg
charg
oxygen
atom
carboxyl
group
repres
hydrogen
bond
acceptor
hba
carbon
atom
methan
repres
hydrophob
center
hpc
pharmacophor
model
gener
proteinligand
complex
use
cmk
peptid
six
compound
fig
gener
set
seven
eightpoint
pharmacophor
model
sarscov
main
proteinas
list
tabl
hypothes
exhibit
differ
featur
due
divers
compound
involv
base
model
extract
common
fourpoint
pharmacophor
distanc
pattern
shown
fig
hba
hbd
hpc
hba
hpc
hba
hbd
hba
hbd
pharmacophor
distanc
pattern
subsequ
use
databas
search
pharmacophor
search
databas
conduct
nci
databas
open
structur
readi
search
tabl
summar
result
similar
search
abovement
fourpoint
pharmacophor
model
constraint
distanc
rang
fig
respect
compound
drug
antivir
probabl
compound
label
name
tabl
eightpoint
pharmacophor
model
obtain
ligbuild
seven
peptid
compound
pharmacophor
peptid
compound
clude
review
hitlist
drug
select
analysi
chemic
structur
bioactiv
document
antihiv
antiopportunist
infect
chemic
compound
databas
contain
approxim
compound
http
govstructsearchanansearchhtm
shown
fig
tabl
respect
note
almost
drug
exhibit
antihiv
activ
activ
mycobacterium
tuberculosi
puromycin
influenza
inde
among
drug
six
compound
alreadi
exhibit
antisarscov
activ
experiment
azauridin
pyrazofurin
ribavirin
dideoxyguanosin
show
pharmacophor
model
lead
discoveri
potent
antisarscov
inhibitor
least
provid
use
clue
fig
show
map
six
compound
fourpoint
pharmacophor
model
map
hba
hbd
hpc
addit
remain
compound
remark
similar
one
six
compound
exampl
azauridin
alexan
arauridin
spongothymidin
emanil
fialuridin
floxuridin
radibud
thymidin
viropt
dideoxyguanosin
angustmycin
c
cordycepin
tubercidin
vengicid
viraa
superposit
compound
shown
fig
summari
result
indic
exist
drug
identifi
pharmacophor
model
could
potenti
inhibitor
sarscov
least
good
lead
compound
antisarscov
drug
design
